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Abstract
We demonstrate that by altering the length of Cas9-associated guide RNA(gRNA) we were able to 
control Cas9 nuclease activity and simultaneously perform genome editing and transcriptional 
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regulation with a single Cas9 protein. We exploited these principles to engineer mammalian 
synthetic circuits with combined transcriptional regulation and kill functions governed by a single 
multifunctional Cas9 protein.
So far no method exists that allows switching between Cas9 nuclease–dependent and –
independent functions with relative ease. The ability of a single Cas9 protein to perform 
genomic modifications while simultaneously modulating transcription would allow a user to 
gain control of two critical cell biomolecules, DNA and RNA. A tool that made this possible 
would be transformative for a variety of applications, such as therapeutic interventions, 
genetic screening and synthetic genetic circuits1–4.
In its native form, Cas9 is directed to a specific DNA sequence by a short gRNA that 
contains 20 nucleotides (nt) complementary to its target. Truncated gRNAs, with 17-nt 
complementarity, have been shown to decrease undesired mutagenesis at some off-target 
sites without sacrificing on-target genome-editing efficiency5. In the same study, however, 
gRNAs containing ≤16 nt showed a drastic reduction in nuclease activity. Analogous to 
earlier experiments examining the effects of increasing numbers of mismatches in a gRNA6, 
we hypothesized that the lack of DNA cleavage with 16-nt gRNA was due not to a lack of 
DNA binding but to an inability of Cas9 to cleave the target substrate after binding.
We targeted Cas9 and a set of truncated gRNAs to the promoter of a transiently transfected 
fluorescent reporter. In agreement with previous results, Cas9 showed robust levels of 
nuclease activity with both 20-nt and 18-nt gRNAs and a sharp loss of function with ≤16-nt 
gRNAs (Supplementary Fig. 1a). To determine whether the lack of DNA modification 
observed with ≤16-nt guides was due to attenuated Cas9 nuclease activity, we fused a potent 
transcriptional activator (VPR) to Cas9 (ref. 7). We then targeted the Cas9-VPR fusion 
product to the same fluorescent reporter and quantified the effect of gRNA length on 
activation. As expected, Cas9-VPR showed minimal activation when a 20-nt gRNA was 
used, but when the gRNA length was decreased, a corresponding increase in activation was 
observed, with maximal activation achieved with 16-nt or 14-nt gRNAs (Supplementary Fig. 
1b). Cas9-VPR showed nuclease activity similar to that of wild-type Cas9 with 20-nt or 18-
nt gRNAs, and it demonstrated reporter activation equivalent to that of a fusion between 
nuclease-null Cas9 and VPR (dCas9-VPR) when 16-nt or 14-nt gRNAs were used 
(Supplementary Fig. 1). To assess the generality of this approach, we tested the effects of 
shortened gRNAs using two other Cas9 orthologues8 and observed a similar capacity of 
shortened gRNAs to inhibit nuclease activity while still allowing interaction with DNA 
(Supplementary Fig. 2).
We next sought to determine whether our gRNA engineering paradigm would enable us to 
modulate Cas9 activity at endogenous target genes. Using 20-, 16- and 14-nt gRNAs, we 
targeted Cas9, Cas9-VPR and dCas9-VPR to the promoter regions of genes encoding 
structural proteins (ACTC1 and TTN), a long noncoding RNA (MIAT) and a protein critical 
to tissue oxygen delivery (HBG1). Cas9-VPR was able to induce target chromosomal gene 
expression with 16-nt and 14-nt gRNA, but not with 20-nt gRNA (Fig. 1a–c and 
Supplementary Fig. 3). In addition, Cas9-VPR in conjunction with a 14-nt gRNA was able 
to generate expression equivalent to at least 40% of the expression level for all targets tested 
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when compared with dCas9-VPR with a 20-nt gRNA. In addition to measuring gene 
induction, we also examined the amount of Cas9-induced insertions and deletions (indels) in 
the targeted regions. For ACTC1 and MIAT, mutagenesis was observed only with 20-nt 
gRNAs (Fig. 1a,b), whereas for TTN and HBG1, indels were observed with both 20-nt and 
16-nt gRNAs (Fig. 1c and Supplementary Fig. 3).
To further characterize 14- and 20-nt gRNAs, we generated a series of spacer-mismatched 
fluorescent reporter plasmids and performed genome-wide RNA sequencing 
(Supplementary Figs. 4 and 5). The results as a whole suggested that 14-nt gRNAs showed a 
decrease in mismatch tolerance and no significant increase in undesired off-target activity.
Having demonstrated an ability to modulate Cas9 nuclease activity by simply altering gRNA 
length, we set out to determine whether we could perform nuclease-independent and 
nuclease-dependent functions simultaneously in a population of cells with a single Cas9 
protein. We introduced Cas9 or Cas9-VPR along with a series of 14-nt gRNAs to target TTN 
and MIAT for activation and 20-nt gRNAs to target ACTC1 for mutation. Compared with 
wild-type Cas9, Cas9-VPR exhibited robust TTN and MIAT gene induction while also 
generating a similar level of genomic mutation at the ACTC1 locus (Fig. 1d and 
Supplementary Fig. 6). As an extension of these experiments, we also found that by using 
aptamer-based gRNA tethering systems, we could endow Cas9 in cell lines and organisms 
already expressing the protein with the ability to concurrently cut and activate a set of 
targets (Supplementary Fig. 7).
Next, we generated a number of synthetic transcriptional devices and layered circuits in 
human cells using the multifunctional CRISPR (clustered, regularly interspaced, short 
palindromic repeats)–multifunctional Cas9 protein system to test the utility of such a system 
for synthetic biology purposes. We first developed a library of our previously described 
CRISPR-repressible promoters (CRPs)9 to identify promoter architectures that allowed us to 
achieve efficient Cas9-VPR–mediated transcriptional repression (Supplementary Figs. 8 and 
9). We then performed a parallel experiment using the high-performance member of this 
promoter library (CRP-8, referred to as CRP-a in subsequent experiments) and confirmed 
similar repression efficiency (approximately tenfold repression) using dCas9 or Cas9-VPR 
with a 14-nt gRNA to this promoter (Fig. 2a).
We then evaluated the use of Cas9-VPR and 14-nt gRNAs in a single cell to achieve 
simultaneous transcriptional activation and repression. A CRP was placed upstream of 
enhanced yellow fluorescent protein (EYFP), and a CRISPR-activatable promoter (CAP) 
was placed upstream of tdTomato fluorescent protein. We transfected HEK293FT cells with 
both promoters, along with other circuit regulatory elements. Flow cytometry analysis 48 h 
after transfection showed that simultaneous repression and activation of the fluorescent 
reporters (~15-fold) were achieved with two 14-nt gRNAs that targeted Cas9-VPR to the 
two promoters (Fig. 2b and Supplementary Fig. 8b).
Subsequently, we designed a genetic kill switch in which a 20-nt gRNA that cut within a 
CAP was expressed under a tetracycline response element (TRE) promoter9,10. In the 
absence of a small-molecule inducer (doxycycline), Cas9-VPR in combination with 
Kiani et al. Page 3









constitutively expressed 14-nt gRNA for the same target in the CAP activated expression of 
EYFP. After the addition of doxycycline, the 20-nt guide enabled Cas9-VPR to bind and cut 
within the CAP, leading to decreased EYFP expression (Fig. 2c and Supplementary Fig. 8c). 
When a similar circuit was used in which Cas9-VPR was replaced with dCas9-VPR, 
doxycycline addition led to an increase rather than a decrease in EYFP expression (Fig. 2c). 
Further analysis of this circuit revealed the dynamics and dosage response within this circuit 
topology (Supplementary Note 1 and Supplementary Figs. 10 and 11).
We then tested a genetic kill-switch design that operated by modulating the availability of 
Cas9-VPR in a cell. In our circuit, in the presence of a pair of full-length 20-nt gRNAs 
targeting the middle of the Cas9-VPR coding sequence, the guides directed Cas9-VPR to cut 
and disable itself and, by doing so, decreased the available pool of Cas9-VPR in the cell, 
ultimately causing a decrease in Cas9-VPR– and 14-nt gRNA–mediated inhibition and 
activation of the two fluorescent reporters (Supplementary Fig. 12).
Next, we developed and analyzed progressively complex genetic kill switches that 
ultimately incorporated the three discussed functions of a single Cas9-VPR protein. To this 
end, we used one of our previously characterized transcription activator–like effector 
repressors (TALERs)11,12 and first tested whether Cas9-VPR could cleave within the 
TALER coding sequence and decrease the amount of available TALER, thereby negating its 
repression of EYFP (Supplementary Fig. 13). We then generated a modified U6 promoter9 
regulated by TALERs that enabled us to connect the genetic kill switch with a Cas9-VPR 
14-nt gRNA repression device. Transfection of HEK293FT cells with this circuit led to 
repression of output EYFP upon the addition of input 20-nt gRNAs that cut within the 
TALER coding sequence (Supplementary Fig. 14). Finally, we combined and interconnected 
the genetic kill switch described in Supplementary Figure 14 with a Cas9-VPR–mediated 
transcriptional activation device to build a multilayered genetic circuit that simultaneously 
incorporated CRISPR-mediated transcriptional repression, activation and DNA cleavage in a 
single circuit to modulate the output (Fig. 2d and Supplementary Fig. 8d). Flow cytometry 
analysis 24 and 48 h after transfection of HEK293FT cells revealed a functional circuit 
regulated by the input 20-nt gRNA against TALER (Fig. 2d).
The ability of a single Cas9 protein to regulate RNA production while also maintaining the 
capacity to cleave DNA will be of great use in deciphering complex biological interactions 
and developing artificial genetic circuits. A promising use of our gRNA design principles 
will be in easily extending existing Cas9-based genome editing systems to concurrently 
modulate gene expression. This is particularly appealing in cases where considerable effort 
has been expended toward the generation of Cas9-expressing strains of mice or other labor-
intensive and costly model systems13,14. Further, our data suggest that nuclease-positive 
Cas9 can be easily endowed with other previously described dCas9 activities15,16 such as in 
vivo chromosomal tracking17, and they could facilitate the development of multifunctional 
synthetic genetic safety circuits with potential biomedical applications.
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Fluorescent reporter assay for quantifying Cas9 activation
Fluorescent reporter experiments described in Supplementary Figures 1 and 2 were 
conducted with a plasmid (Addgene, 47320) modified to include an extra gRNA binding site 
100 bp upstream of the original one. For ST1 and SA Cas9 experiments, the protospacer 
remained the same but the PAM sequence was modified as needed for ST1 or SA Cas9. All 
experiments described in Supplementary Figure 4 were conducted with a reporter with a 
single gRNA binding site. Reporter 1 was Addgene 47320, and reporters 2 and 3 were 
similar to reporter 1 except that the protospacer and PAM (in bold) were changed to contain 
the sequences GGGGCCACTAGGGACAGGATTGG and 
AAGAGAGACAGTACATGCCCTGG, respectively. HEK293T cells were cotransfected 
with gRNAs of various lengths, the indicated Cas9 protein and reporter and an EBFP2 
transfection control. gRNA sequences for these experiments can be found in Supplementary 
Note 2. Cells were analyzed by flow cytometry 48 h after transfection and then, when 
necessary, were lysed for extraction of genomic DNA.
Reporter deletion analysis
DNA was extracted with QuickExtract DNA extraction solution (Epicentre). DNA was then 
used for PCR to amplify specific regions. PCR primers can be found in Supplementary Note 
2. The amplified samples were then run on a 2% agarose gel stained with GelGreen 
(Biotium) and visualized using Gel Doc EZ (Bio-Rad). Band intensity was quantified using 
GelAnalyzer.
Quantitative RT-PCR analysis
Samples were lysed and RNA was extracted using the RNeasy Plus mini kit (Qiagen). 
cDNA was made using the iScript cDNA synthesis kit (Bio-Rad) with 500 ng of RNA. Kapa 
SYBR Fast universal 2× quantitative PCR (qPCR) master mix (Kapa Biosystems) was used 
for qPCR, with 0.5 µl of cDNA used for each reaction. Activation was analyzed with the 
CFX96 Real-Time PCR detection system (Bio-Rad). Gene expression levels were 
normalized to levels of ACTB. qPCR primers can be found in Supplementary Note 2.
Analysis of endogenous indels
DNA was extracted from 24-well plates using 350 µl of QuickExtract DNA extraction 
solution (Epicentre) according to the manufacturer’s instructions. Amplicon library 
preparation was done with two PCRs. The first PCR was used to amplify from the genome 
and add appropriate barcodes and parts of adapters for Illumina sequencing. The second 
PCR extended the Illumina adapters. In the first PCR, 5 µL of extracted DNA was used as a 
template in a 100-µL Kapa HiFi PCR reaction run for 30 cycles. PCR products were then 
purified using a homemade solid-phase reversible-immobilization bead mixture and eluted 
in 50 µL of elution buffer. For the second PCR, 2 µL of the first-round PCR was used as a 
template in a 25-µL reaction, and PCRs were run for a total of nine cycles. PCR products 
were then run on an agarose gel, extracted and column purified. Equal amounts of each 
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sample were then pooled and sequenced on an Illumina MiSeq using the paired-end 150 
MiSeq Nano kit. PCR primers for this analysis can be found in Supplementary Note 2.
We merged mate pair reads into single contigs using FLASH18. Each contig was then 
mapped to a custom reference representing the three amplicons with bwa mem19. SAM 
output files were then converted to BAM files, and pileup files were generated for each 
sample with SAMtools20. We then analyzed pileup files with custom Python scripts to 
determine observed mutation rates. Mutations were counted only if they spanned some 
portion of the sgRNA target site. In addition, base quality scores of ≥28 were required for 
any mutations to be called. To minimize the impact of sequencing errors, we excluded single 
base substitutions in this analysis.
RNA sequencing for quantifying activator specificity
For each sample, 200 ng of total RNA was polyA selected using a Dynabeads mRNA 
purification kit (Life Technologies). The RNA was then DNAse-treated with Turbo DNase 
(Life Technologies) and cleaned up with Agencourt RNAClean XP beads (Beckman 
Coulter). RNA-Seq libraries were made using the NEBNext Ultra RNA library prep kit for 
Illumina (New England BioLabs) according to the manufacturer’s instructions with 
NEBNext multiplex oligos (New England BioLabs). Libraries were analyzed on a 
BioAnalyzer using a High Sensitivity DNA analysis kit (Agilent). Libraries were then 
quantified using a Kapa Library Quantification Kit (Kapa Biosystems) and pooled to a final 
concentration of 4 nM. Sequencing was performed on an Illumina NextSeq instrument with 
paired end reads. Reads were aligned to the hg19 UCSC Known Genes annotations using 
RSEM v1.2.1 (ref. 21) and were analyzed in Python and R. Differential gene-expression 
analysis was done using the Voom22 and Limma23 packages in R for all genes with ≥1 
transcript per million mapped reads in each replicate, and a one-way within-subjects analysis 
of variance was performed on the number of differentially expressed genes for each 
condition to quantify off-target effects, where differential expression was defined by a 
Benjamini-Hochberg adjusted P value of <0.05 and fold change of >2 or <0.5.
Statistical analysis
All t-tests were performed via the GraphPad QuickCalcs website (http://graphpad.com/
quickcalcs/ttest1/?Format=SEM; accessed June 2015). Raw data are provided in the 
Supplementary Data.
Cell culture for endogenous target mutation or activation or deletion reporter
HEK293T cells (a gift from P. Mali, UCSD, San Diego, California, USA) were cultivated in 
Dulbecco’s modified Eagle’s medium (DMEM) (Life Technologies) with 10% fetal bovine 
serum (FBS) (Life Technologies) and penicillin-streptomycin (Life Technologies). Incubator 
conditions were 37 °C and 5% CO2. Cells were tested for mycoplasma yearly. Cells were 
seeded into 24-well plates at 50,000 cells per well and transfected with 200 ng of Cas9 
construct, 10 ng of guide, 60 ng of reporter (for reporter experiments) and 25 ng of EBFP2 
(for reporter experiments) with Lipofectamine 2000 (Life Technologies). After transfection, 
cells were grown for 48–72 h and lysed for either RNA or DNA extraction. gRNA for these 
experiments can be found in Supplementary Note 2.
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Cell culture for circuit experiments
Experiments were carried out in HEK293FT cells obtained from ATCC and maintained in 
DMEM (CellGro) supplemented with 10% FBS (PAA Laboratories), 1% l-glutamine–
streptomycin–penicillin mix (CellGro) and 1% nonessential amino acids (HyClone) at 37 °C 
and 5% CO2 and tested for mycoplasma contamination. Transfections were performed using 
Lipofectamine LTX and Attractene reagents (Qiagen). Cells were seeded the day before 
transfection at 2 × 105 cells per well in a 24-well plate. Dosages of plasmids used for the 
transfection of synthetic circuits are presented in Supplementary Note 3. In control 
experiments, we replaced the DNA plasmid under study with an equivalent amount of empty 
DNA plasmid to keep the total amount of transfected DNA constant among the groups. For 
transfections involving Attractene reagent, cocktails of plasmid DNAs were mixed and 
added to serum-free DMEM to a total volume of 70 µl. 1.5–2 µl of Attractene was then 
added to each tube of DNA-DMEM mixture, and tubes were gently mixed and kept at room 
temperature for 25 min to allow the DNA-liposome complex to form. For experiments 
involving Lipofectamine LTX, cocktails of plasmid DNAs, serum-free DMEM and the Plus 
reagent were mixed and incubated for 10 min. In parallel, LTX reagent was mixed with the 
serum-free media and incubated for the same period of time. After the 10-min incubation, 
the two reagents were mixed and incubated for an additional 30 min. Fresh medium was 
added to the cells directly before transfection (500 ml of DMEM with supplements). The 
DNA-reagent solution was then added dropwise to the wells. Induction of the circuit was 
performed at this time as well via the addition of doxycycline.
Vector design and construction
Reporter gRNA (Addgene, 48672), dCas9-VPR (Addgene, 63798) and Cas9 (Addgene, 
41815) were described previously. Cas9-VPR was cloned via Gateway assembly 
(Invitrogen) based on the Cas9 plasmid. gRNAs for endogenous targets were cloned into 
Addgene 41817 and transiently transfected. Plasmids used for synthetic circuits were 
constructed using the Gateway system, and the sequences are provided in Supplementary 
Note 4. The U6-driven gRNA expression cassettes were ordered as gblocks from IDT and 
cloned into a plasmid backbone using Golden Gate cloning. The library of CRPs was 
ordered as gene fragments from IDT and assembled into an appropriate promoter entry 
vector. Cas9-VPR plasmids used in this study have been submitted to Addgene (68495, 
68496, 68497 and 68498).
Flow cytometry for circuit experiments
Flow cytometry data were collected 48 h after transfection. Cells were trypsinized and 
centrifuged at 453g for 5 min at 4 °C. The supernatant was then removed, and the cells were 
resuspended in Hank’s balanced salt solution without calcium or magnesium supplemented 
with 2.5% FBS. A BD LSR II was used to obtain flow cytometry measurements with the 
following settings: EBFP, measured with a 405-nm laser and a 450/50 filter; EYFP, 
measured with a 488-nm laser and a 530/30 filter; and tdTomato, measured with a 561-nm 
laser and a 695/40 filter. Nontransfected controls were included in each experiment. Sample 
sizes were predetermined for each experiment on the basis of initial pilot experiments. We 
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also ensured that we gathered at least 100,000 flow cytometry events per biological 
replicate. Raw data are provided in the Supplementary Data.
Statistical analysis for circuit experiments
Flow cytometry data were converted from arbitrary units to compensated molecules of 
equivalent fluorescein (MEFL)24 using the Tool-Chain to Accelerate Synthetic Biological 
Engineering (TASBE) characterization25 (http://web.mit.edu/jakebeal/www/Publications/
MIT-CSAIL-TR-2012-008.pdf). In this process an affine compensation matrix is computed 
from single positive and blank controls. Measurements of FITC dye are calibrated to MEFL 
using SpheroTech RCP-30-5-A beads, and mappings from other channels to equivalent 
FITC are computed from cotransfection of constitutive blue, yellow and red fluorescent 
proteins, each controlled by the CAG promoter on its own otherwise identical plasmid. 
Nontransfected controls were included in each experiment in this study. Sample sizes were 
predetermined for each experiment. Data shown in the figures are the geometric mean and 
s.d. for cells expressing the transfection marker EBFP or mKate on the basis of the MEFL 
threshold set. More precisely, we selected a threshold as a cutoff for each data set on the 
basis of the observed constitutive fluorescence distributions and excluded data below that 
threshold for being too close to the nontransfected population. Then we divided MEFL data 
by constitutive fluorescent protein expression into logarithmic bins at ten bins per decade 
and calculated the geometric mean and variance for the data points in each bin. We removed 
the high outliers by excluding bins without at least 100 data points. In fact, we calculated 
both population and per-bin geometric statistics using this filtered set of data. Exclusion 
criteria for samples during flow cytometry analysis were as follows: samples containing less 
than 10% of the number of events or less than 10% of the fraction of successful transfections 
of the mode for the batch in which they were collected.
Code availability
Scripts for determining mutation rates are available upon request.
Reproducibility
Sample sizes for each experiment were chosen on the basis of an initial pilot experiment and 
were further guided by sample sizes in similar experiments and publications. No 
randomization or blinding was used in the course of our experiments. No data were excluded 
from analysis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Activation and cutting of endogenous genes in HEK293T cells. (a–c) RNA expression and 
mutagenesis analysis of the genes ACTC1 (a), MIAT (b) and TTN (c). Each sample was 
transfected with the indicated Cas9 construct and gRNA of a particular length. Points 
represent data from two individual transfections. (d) Multiplexed activation and cutting of 
ACTC1, MIAT and TTN. The constructs were transfected with 20-nt ACTC1 gRNA and 14-
nt MIAT and TTN gRNAs simultaneously. Points represent data from two individual 
transfections.
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Design and experimental analysis of human cells with multifunctional CRISPR devices and 
circuits. (a) Top, schematic of a repression device using Cas9-VPR and 14-nt gRNA. 
Bottom, the geometric mean and s.d. of EYFP expression for cells expressing >107 
molecules of equivalent fluorescein (MEFL) of transfection marker enhanced blue 
fluorescent protein (EBFP). n = 3 independent technical replicates from three experiments (n 
= 2 for Cas9-VPR + gRNA). (b) Top, schematic of parallel Cas9-VPR and14-nt gRNA–
based transcriptional repression and activation devices in a single cell. Bottom, the 
geometric mean and s.d. of EYFP and tdTomato expression for cells expressing >107 MEFL 
of transfection marker EBFP. n = 4 independent technical replicates combined from three 
experiments. (c) Top, schematic of a genetic kill switch designed to incorporate Cas9-VPR 
DNA cleavage and transcriptional activation functions. Bottom, the geometric mean and s.d. 
of EYFP expression for cells expressing >3 × 107 MEFL of transfection marker EBFP. n = 3 
independent technical replicates from three experiments (n = 2 for Cas9-VPR without 
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doxycycline). rtTA, reverse tetracycline-controlled transactivator; iRFP, near-infrared 
fluorescent protein. (d) Left, genetic kill-switch circuit incorporating all three functions of 
Cas9-VPR: DNA cleavage, transcriptional activation and repression. Right, the geometric 
mean and s.d. of EYFP expression for cells expressing >107 MEFL of transfection marker 
mKate. n = 4 independent technical replicates from three experiments (n = 2 in 48-h 
groups). pConst, constitutively active promoter (e.g., CAG or hEF1-a).
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